Invasive fungal infections are a serious, escalating health issue. They cause severe disease with high death rates and are very costly to the health system. Current drugs often have suboptimal efficacy and cause side effects. New drugs are needed urgently. Many fungi, including the AIDS-related pathogen, Cryptococcus neoformans, secrete phospholipase B (Plbp) to facilitate infection. We will identify and investigate the Plbp secretion pathway as a novel anti-fungal drug target.
New multi-scale seed dispersal models for improved regional weed management. This project will exploit recent advances in ecological and atmospheric modelling with the aim to build improved models of seed dispersal across landscapes to anticipate weed spread. Damaging invasive plants are rapidly transforming landscapes and altering ecosystem function worldwide. The speed and direction of weed spread determines the success or failure of costly containment and control actions, however we lack the ....New multi-scale seed dispersal models for improved regional weed management. This project will exploit recent advances in ecological and atmospheric modelling with the aim to build improved models of seed dispersal across landscapes to anticipate weed spread. Damaging invasive plants are rapidly transforming landscapes and altering ecosystem function worldwide. The speed and direction of weed spread determines the success or failure of costly containment and control actions, however we lack the ability to adequately predict spread. New models that combine micrometeorological measurements, within-canopy turbulence and topographic variation in wind flows will be designed to better predict where dispersal will occur. In this project, these improved predictions are planned to be combined with decision models to direct the management of invasive species across entire landscapes.Read moreRead less
Melanotransferrin: A “Missing Link” And A Novel Pharmacological Target For Treatment
Funder
National Health and Medical Research Council
Funding Amount
$613,848.00
Summary
Despite >30 years of research, the precise function of the protein, melanotransferrin (MTf), is unknown. However, we have breakthrough evidence that MTf stimulates WNT signalling as a major driver in cancer progression. We will investigate this hypothesis, which will underpin new cancer therapies. Indeed, we designed a new class of drugs that target the WNT pathway via up-regulating the WNT inhibitor, NDRG1. This drug (DpC) inhibits MTf expression to block tumour cell growth and metastasis.
Transient Tissue ‘priming’ Via FAK Inhibition To Impair Pancreatic Cancer Progression And Improve Sensitivity To Gemcitabine/Abraxane
Funder
National Health and Medical Research Council
Funding Amount
$643,848.00
Summary
The success of cancer drugs is dependent on many factors including the properties of the tumour tissue. As a tumour grows it changes the tissue around it, and this affects response to treatment. Combining classical biology with engineering to generate 3D models that mimic tumours, along with cutting-edge imaging technology and mouse models, we will target FAK-controlled cancer cell pathways that sense tissue changes, together with already approved cancer drugs to improve patient outcome.
Therapeutic Targeting Of Cell Cycle Checkpoint Aberrations In Pancreatic Cancer: Personalised Medicine In Action
Funder
National Health and Medical Research Council
Funding Amount
$634,354.00
Summary
Less than 5% of people with pancreatic cancer (PC) survive 5 years, and the odds of patients beating this disease have remained unchanged for 50 years. Consequently, there is an urgent need to develop novel treatment approaches for this highly aggressive cancer. Our study aims to define novel therapeutic strategies for PC utilising specific anti-proliferative therapies and a personalised “companion biomarker” directed strategy.
Achieving Targeted Delivery Of Drugs To Uterine Muscle In Women For The Prevention Of Preterm Labour
Funder
National Health and Medical Research Council
Funding Amount
$469,008.00
Summary
We have patented liposomes targeted to the uterus, which enable us to deliver drugs specifically to the muscle cells of the uterus, increasing safety. The liposomes can be loaded with drugs that either block or promote contractions, creating a versatile drug delivery system that could treat premature labour or postpartum haemorrhage which are major clinical problems. We seek support to demonstrate their effectiveness in mouse and primate models of preterm labour prior to human studies.
Evaluating The Genetic Contribution To Rheumatic Heart Disease Pathogenesis In Australian Aboriginal And Torres Strait Islander Communities
Funder
National Health and Medical Research Council
Funding Amount
$1,782,074.00
Summary
Rheumatic heart disease is highly prevalent in Aboriginal people in Australia and leads to early cardiac disease. Despite decades of research, the underlying genetic mechanisms for why it occurs are not well understood. We are conducting a genetic study to better understand why some people are susceptible to RHD and others are not. The study will involve substantial Aboriginal leadership and consultation and will be a model for the conduct of genetic studies in Aboriginal populations.
The Effects Of Tonic Muscle Pain On The Sympathetic And Somatic Motor Systems In Human Subjects
Funder
National Health and Medical Research Council
Funding Amount
$462,948.00
Summary
The main objective of this proposal is to reveal the effects of nociceptive reflexes in humans, and thus identify their functional and clinical implications. By performing invasive recordings from the nerves that control blood vessels and muscles in healthy volunteers subjected to long-lasting (~1 hour) experimental pain, this work will increase our understanding of the adaptive changes that pain induces and improve treatments to prevent pain from becoming chronic.
Psychosocial Aspects Of Genomic Testing For Breast Cancer Risk
Funder
National Health and Medical Research Council
Funding Amount
$108,902.00
Summary
Assessing a woman’s breast cancer risk by profiling polygenic risk represents a new approach in the familial cancer setting. My study is part of a program of research that aims to facilitate translation of polygenic risk information into clinical practice. For this, I will invite 400 women to receive their personal polygenic result and i) assess interest in receiving this result; ii) assess psychological and behavioural outcomes of receiving or not receiving their personal polygenic risk result
Most eye diseases have a genetic contribution, whether rare disorders affecting children such as retinoblastoma or congenital cataracts through to common disorders of older people such as myopia, age-related macular degeneration or glaucoma. We will continue our successful research to find genes that cause these diseases and use this to improve patient care and prevent blindness. We will work out how families can use this genetic information to participate in trials to develop new treatments.